PT2403951E - Mutantes de adenovírus e1a e e1b de tumores - Google Patents

Mutantes de adenovírus e1a e e1b de tumores Download PDF

Info

Publication number
PT2403951E
PT2403951E PT107492050T PT10749205T PT2403951E PT 2403951 E PT2403951 E PT 2403951E PT 107492050 T PT107492050 T PT 107492050T PT 10749205 T PT10749205 T PT 10749205T PT 2403951 E PT2403951 E PT 2403951E
Authority
PT
Portugal
Prior art keywords
mutants
tumor
selective adenovirus
adenovirus
selective
Prior art date
Application number
PT107492050T
Other languages
English (en)
Inventor
Tony Reid
Farah Hedjran
Shantanu Kumar
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT2403951E publication Critical patent/PT2403951E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT107492050T 2009-03-02 2010-03-02 Mutantes de adenovírus e1a e e1b de tumores PT2403951E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15682209P 2009-03-02 2009-03-02

Publications (1)

Publication Number Publication Date
PT2403951E true PT2403951E (pt) 2016-01-29

Family

ID=42710189

Family Applications (2)

Application Number Title Priority Date Filing Date
PT107492050T PT2403951E (pt) 2009-03-02 2010-03-02 Mutantes de adenovírus e1a e e1b de tumores
PT151820867T PT3029144T (pt) 2009-03-02 2010-03-02 Mutantes e1a e e1b de adenovírus seletivos de tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT151820867T PT3029144T (pt) 2009-03-02 2010-03-02 Mutantes e1a e e1b de adenovírus seletivos de tumor

Country Status (15)

Country Link
US (5) US9073980B2 (pt)
EP (4) EP4123030A1 (pt)
JP (5) JP6072414B2 (pt)
KR (4) KR101922539B1 (pt)
CY (1) CY1122385T1 (pt)
DK (2) DK2403951T3 (pt)
ES (2) ES2557812T3 (pt)
HR (2) HRP20151396T1 (pt)
HU (2) HUE026386T2 (pt)
LT (1) LT3029144T (pt)
PL (2) PL3029144T3 (pt)
PT (2) PT2403951E (pt)
SI (2) SI3029144T1 (pt)
SM (1) SMT201500329B (pt)
WO (1) WO2010101921A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4123030A1 (en) 2009-03-02 2023-01-25 The Regents of the University of California Tumor-selective e1a and e1b mutants
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017336546A1 (en) 2016-09-27 2019-05-02 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
SG11201906976YA (en) * 2017-01-30 2019-08-27 Epicentrx Inc Tumor selective tata-box and caat-box mutants
SG11201906973TA (en) * 2017-01-30 2019-08-27 Epicentrx Inc Multiple transgene recombinant adenovirus
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS
EA201990822A1 (ru) * 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
AU2018271999A1 (en) * 2017-05-24 2020-01-16 Epicentrx, Inc. Anti-angiogenic adenovirus
CN111094577A (zh) * 2017-05-26 2020-05-01 埃皮森特Rx股份有限公司 携带转基因的重组腺病毒
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
WO2019191494A1 (en) * 2018-03-28 2019-10-03 Epicentrx, Inc. Personalized cancer vaccines
WO2020046130A1 (en) * 2018-08-31 2020-03-05 Orca Therapeutics B.V. Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (gsk3) and methods of killing aberrant cells
CA3154115A1 (en) 2019-10-08 2021-04-15 Yunan ZHENG Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
CN114262691A (zh) * 2020-09-16 2022-04-01 杭州康万达医药科技有限公司 分离的能够用于表达外源基因的溶瘤腺病毒、载体、治疗剂及其用途
WO2024015876A1 (en) 2022-07-13 2024-01-18 Epicentrx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643567A (en) 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US5902925A (en) 1996-07-01 1999-05-11 Integrated Sensor Solutions System and method for high accuracy calibration of a sensor for offset and sensitivity variation with temperature
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
US20050287120A1 (en) 1997-03-21 2005-12-29 Fisher Paul B Cancer - targeted viral vectors
ATE431421T1 (de) * 1999-01-28 2009-05-15 Onyx Pharma Inc In der e1b-region deletierte, adenovirale shuttle-vektoren
US6764674B1 (en) * 1999-01-28 2004-07-20 Onyx Pharmaceuticals Inc. Adenovirus E1B shuttle vectors
AU2001257611A1 (en) * 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
WO2002018550A1 (en) * 2000-08-25 2002-03-07 The General Hospital Corporation Selective precipitation of viruses
CN1183250C (zh) 2000-12-01 2005-01-05 卫健生物科技有限公司 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法
GB0117198D0 (en) 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
AU2003253992A1 (en) 2002-07-18 2004-02-09 Robert P. Bennett Viral vectors containing recombination sites
AU2003268210A1 (en) * 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
JP2007511212A (ja) 2003-11-14 2007-05-10 ホルム，ペル・ゾンネ 新規アデノウイルス、それをコードする核酸及びその使用
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
JP5484897B2 (ja) * 2007-04-20 2014-05-07 タカラバイオ株式会社 遺伝子治療のためのベクター
EP4123030A1 (en) 2009-03-02 2023-01-25 The Regents of the University of California Tumor-selective e1a and e1b mutants

Also Published As

Publication number Publication date
SMT201500329B (it) 2016-02-25
LT3029144T (lt) 2019-10-25
US9073980B2 (en) 2015-07-07
HRP20191808T1 (hr) 2019-12-27
PL3029144T3 (pl) 2020-06-01
US10876097B2 (en) 2020-12-29
ES2750305T3 (es) 2020-03-25
EP3591059A1 (en) 2020-01-08
EP2403951A4 (en) 2012-08-22
KR101922539B1 (ko) 2018-11-27
HUE026386T2 (en) 2016-06-28
HRP20151396T1 (hr) 2016-03-25
HUE046565T2 (hu) 2020-03-30
US20190136204A1 (en) 2019-05-09
DK2403951T3 (en) 2016-01-11
JP2022023074A (ja) 2022-02-07
SI2403951T1 (sl) 2016-04-29
JP2018113971A (ja) 2018-07-26
KR20110122866A (ko) 2011-11-11
US20230272349A1 (en) 2023-08-31
US20160017294A1 (en) 2016-01-21
EP4123030A1 (en) 2023-01-25
DK3029144T3 (da) 2019-10-21
KR102020018B1 (ko) 2019-09-09
PT3029144T (pt) 2019-10-28
JP2012519014A (ja) 2012-08-23
JP2020078326A (ja) 2020-05-28
US11618888B2 (en) 2023-04-04
JP7326396B2 (ja) 2023-08-15
EP2403951B1 (en) 2015-09-30
EP3029144B1 (en) 2019-07-10
JP6817979B2 (ja) 2021-01-20
KR102150027B1 (ko) 2020-10-26
EP3029144A1 (en) 2016-06-08
PL2403951T3 (pl) 2016-04-29
ES2557812T3 (es) 2016-01-28
JP6072414B2 (ja) 2017-02-01
JP2016028035A (ja) 2016-02-25
KR20180049188A (ko) 2018-05-10
WO2010101921A3 (en) 2011-01-06
SI3029144T1 (sl) 2019-11-29
WO2010101921A2 (en) 2010-09-10
US20210171917A1 (en) 2021-06-10
JP6375273B2 (ja) 2018-08-15
US20110318311A1 (en) 2011-12-29
EP2403951A2 (en) 2012-01-11
KR101752910B1 (ko) 2017-06-30
KR20190104643A (ko) 2019-09-10
EP3591059B1 (en) 2022-07-20
CY1122385T1 (el) 2021-01-27
KR20170077278A (ko) 2017-07-05

Similar Documents

Publication Publication Date Title
PL3029144T3 (pl) Zmutowane geny adenowirusowe E1a i E1b o selektywnym działaniu na guza
HK1244679A1 (zh) 用於治療癌症的溶瘤腺病毒
HRP20170165T1 (hr) Onkolitički adenovirusni vektori i metode i uporabe u vezi s time
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
ZA201301862B (en) Oncolytic adenoviral vectors and methods and uses related thereof
ZA201304260B (en) Adenovirus serotype 26 and serotype 35 filovirus vaccines
GB2486155B (en) Predicting and avoiding operand-store-compare hazards in out- of-order microprocessors
EP2588714A4 (en) HIGH SOLIDS CONTENT AND PROCESS THEREFOR
GB201300849D0 (en) Improvements in and relating to anti back-drive couplings
EP2401715A4 (en) CAPTURE CONTENT CONFIGURATION AND DISTRIBUTION
IL224767A (en) Caries and probiotics / prebiotics
GB0919959D0 (en) Detector heating and/or cooling
IL216190A0 (en) Oncolytic adenoviruses for treating cancer
EP2393497A4 (en) GENE TRANSFER IN VIVO AND EX VIVO INTO RENAL TISSUE USING ADENOVIRAL VECTORS EXPRESSING NO MORE VIRAL GENES
EP2554858A4 (en) CONNECTING BAR AND DOUBLE-SIDED CHANGING MECANISM FOR THIS
PL2206931T3 (pl) Śruba i jej zastosowanie
KR101085051B9 (ko) 고유전 폴리이미드-폴리아닐린 복합체 및 이의 제조방법
WO2011008850A9 (en) H3k27me3 and cancer
AP2013006972A0 (en) Adenovirus serotype 26 and serotype 35 filovirus vaccines
HK1128388A2 (en) Visual and synchronous translation system
AU2010903663A0 (en) Hot and Cold water diverter
IL218428A0 (en) Multi-site modified sp1 ploypeptides and uses thereof
AU326656S (en) Electric condiment mill